stockportfolio.pro
Amylyx Pharmaceuticals, Inc. (AMLX)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
Amylyx Pharmaceuticals, Inc. revenue & earnings — last 5 fiscal years
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $285,000 | $22.23M | $380.79M | $87.37M | $0 |
| Gross profit | — | $19.24M | $355.35M | $-37.26M | — |
| Net income | $-87.93M | $-198.38M | $49.27M | $-301.74M | $-144.74M |
| Net margin | -30853.0% | -892.4% | 12.9% | -345.4% | — |
Source: Amylyx Pharmaceuticals, Inc. SEC filings (10-K).
Explore 5 years of Amylyx Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AMLX in your portfolio →
Amylyx Pharmaceuticals, Inc. financial history by metric
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc. — frequently asked questions
What is Amylyx Pharmaceuticals, Inc.'s revenue?
Amylyx Pharmaceuticals, Inc. (AMLX) reported revenue of $0 for fiscal year 2025, down 100.0% from the prior year, according to its SEC filings.
Is Amylyx Pharmaceuticals, Inc. profitable?
No — AMLX reported a net loss of $-144.74M in fiscal 2025.
What is AMLX's P/E ratio?
Amylyx Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Amylyx Pharmaceuticals, Inc. have?
As of fiscal year 2025, AMLX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Amylyx Pharmaceuticals, Inc.'s market cap?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalization of about $1.49B, based on the latest data in our nightly-refreshed cache.
When does Amylyx Pharmaceuticals, Inc.'s fiscal year end?
AMLX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Amylyx Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 5 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.